Antibody-engineered nanoparticles selectively inhibit mesenchymal cells isolated from patients with chronic lung allograft dysfunction

Emanuela Cova, Miriam Colombo, Simona Inghilleri, Monica Morosini, Simona Miserere, Jesus Peñaranda-Avila, Benedetta Santini, Davide Piloni, Sara Magni, Furio Gramatica, Davide Prosperi, Federica Meloni

Research output: Contribution to journalArticlepeer-review

Abstract

Aims: Chronic lung allograft dysfunction represents the main cause of death after lung transplantation, and so far there is no effective therapy. Mesenchymal cells (MCs) are primarily responsible for fibrous obliteration of small airways typical of chronic lung allograft dysfunction. Here, we engineered gold nanoparticles containing a drug in the hydrophobic section to inhibit MCs, and exposing on the outer hydrophilic surface a monoclonal antibody targeting a MC-specific marker (half-chain gold nanoparticles with everolimus). Materials & methods: Half-chain gold nanoparticles with everolimus have been synthesized and incubated with MCs to evaluate the effect on proliferation and apoptosis. Results & discussion: Drug-loaded gold nanoparticles coated with the specific antibody were able to inhibit proliferation and induce apoptosis without stimulating an inflammatory response, as assessed by in vitro experiments. Conclusion: These findings demonstrate the effectiveness of our nanoparticles in inhibiting MCs and open new perspectives for a local treatment of chronic lung allograft dysfunction.

Original languageEnglish
Pages (from-to)9-23
Number of pages15
JournalNanomedicine
Volume10
Issue number1
DOIs
Publication statusPublished - Jan 1 2015

Keywords

  • antifibrotic agent
  • bronchiolitis obliterans syndrome
  • chronic lung allograft dysfunction
  • mesenchymal cell
  • targeted drug-loaded nanoparticle

ASJC Scopus subject areas

  • Materials Science(all)
  • Bioengineering
  • Biomedical Engineering
  • Medicine (miscellaneous)
  • Development
  • Medicine(all)

Fingerprint Dive into the research topics of 'Antibody-engineered nanoparticles selectively inhibit mesenchymal cells isolated from patients with chronic lung allograft dysfunction'. Together they form a unique fingerprint.

Cite this